Memory is a fragile, fickle thing. Almost every adult experiences a memory lapse occasionally. In younger people, shrugging it off or ignoring it may be the norm. As people hit their 40s, resignation that memory loss is a consequence of aging creeps into the apologies. In the 21st century, the possibility that memory lapses represent Alzheimer disease (AD) dementia has fostered a new anxiety. The specter of "Alzheimer's" lurking in everyday memory lapses tends to make a name forgotten or a set of keys misplaced all the more memorable.
Almost like the famous Catch-22, conventional wisdom about memory complaints, without objective evidence of impairment, had been that if someone had enough insight to consider that he or she might have a memory problem, then there probably was not a notable problem. While it is true that many, if not most, persons with symptomatic cognitive impairment lack insight into their cognitive deficits and their consequences, some individuals who have "normal" performance on neuropsychological testing are capable of detecting declines in their own cognition. To be sure, confidence in one's own mental abilities is subject to all manner of vagaries and can be colored by depression, anxiety, or just a tendency to pessimism or hypochondriasis. Yet longitudinal studies of subjective memory impairment (SMI) show it to be a predictor for dementing illness. The risk in SMI of declining to a diagnosis of MCI was 10% over 3 years in one study, 1 about 3 times higher than seen in persons without SMI.
In this issue of Neurology ® , Scheef et al. 2 produce another piece of evidence that SMI may represent incipient brain disease. They show, first, that there are differences in 18 fluoro-deoxyglucose (FDG)-PET imaging and structural MRI in persons in their 60s with subjective complaints compared to persons lacking subjective complaints. SMI subjects showed hypometabolism on FDG-PET in the right precuneus, an area associated with AD pathophysiology, as well as hypermetabolism in the right hippocampus.
Reduced volume of the right hippocampus occurred in the SMI group compared to the controls. Other reports have also shown that SMI subject groups include a higher proportion of persons with changes consistent with incipient AD on structural MRI, [3] [4] [5] FDG-PET, 6 amyloid PET, 7 and changes in CSF, 8 compared to cognitively normal persons without memory complaints. Scheef et al. also showed that the group with SMI experienced longitudinal decline on memory testing but not on 2 tests of executive functioning. This latter finding is novel. The context in which SMI is diagnosed is very important. In Scheef et al., participants were drawn from a clinic to which they were referred because of memory complaints. The authors defined SMI using a single question: "Do you feel like your memory is becoming worse?" If the participant answered "Yes" or "Yes but this doesn't worry me," they were classified as SMI. Importantly, the authors also required that someone else verify the memory complaints. In addition, normal cognition by objective testing was required. The authors used a 10-item list learning procedure. The SMI group appeared slightly worse at the baseline testing on learning and recall than the controls, but the difference was not significant. A different context might have changed the results. Had the subjects been recruited by invitation or had informant verification not been required, participants with more benign SMI might have been overrepresented and the link with biomarkers and future memory decline might have been weaker.
It is likely that most lay persons would include a variety of concerns under "bad memory," such as difficulties with names and loss of mental agility. Therefore, affirmation of decline in memory could have resulted from inefficiencies in multiple cognitive domains, not just memory. A valuable insight from the current study was that performance in the SMI group declined on verbal and visual recall tasks but not on Trail-Making or verbal fluency tests. A caution with this conclusion, though, is that the execu-tive tests used by Scheef et al. might have lacked sensitivity. With that caveat in mind, the results are consistent with the hypothesis that the dominant underlying process driving SMI is based on AD pathophysiology, with memory loss representing the earliest manifestation of a series of characteristic biochemical and structural anatomic changes now called preclinical AD. 9 The construct of SMI is a challenging one to integrate into clinical practice because of its subtleties. SMI is a relevant issue only in the elderly, but there is no one age cutoff. Asking the key question "Do you feel like your memory is becoming worse?" in a nonjudgmental, nonhurried way is critical. Probing specific aspects of daily functioning may help distinguish between benign and worrisome concerns. Affirmative responses to "trouble following a group conversation" or "getting lost on familiar streets" have greater specificity than "trouble with names" or "forgetting things from one minute to the next." 10 Excluding depression, anxiety, and secondary gain in work or interpersonal relationships is necessary. Neuropsychological testing is invaluable in patients with SMI, but the assessment of memory must include more challenging tests. Conversely, extensive imaging may not be indicated unless the neuropsychological testing shows substantial deficits (i.e., taking the patient out of the category of SMI). Despite the recognition that SMI predicts future dementia, the rate of development of MCI or dementia in persons with SMI is certainly low. 1 The concept of "low but not zero risk" is not easy to convey to an anxious patient. If SMI is the diagnosis, a discussion could also lead to a review of vascular risk factors and mood, with interventions in each if indicated. SMI should be taken seriously: no more patting patients on the head and sending them on their way. clinical trials sponsored by Janssen Pharmaceuticals; and receives research support from the NIH. Go to Neurology.org for full disclosures.
